Novel pyrido[3,4-d]pyrimidin-8-one derivative having protein kinase inhibitory activity, and pharmaceutical composition for preventing, alleviating, or treating cancer, comprising same
A derivative, 4-d technology, applied in the direction of drug combination, organic active ingredients, medical preparations containing active ingredients, etc., can solve problems such as inability to establish treatment strategies and failure to achieve clinical therapeutic effects
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0429] N-(3-(2-(cyclopropylamino)-7-methyl-8-oxo-7,8-dihydropyrido[3,4-d]pyrimidin-6-yl)-4-methyl phenyl)-3-(trifluoromethyl)benzamide
[0430]
[0431] Step 1: Methyl 5-bromo-2-(methylthio)pyrimidine-4-carboxylate
[0432]
[0433]Acetyl chloride (1.1 equivalents, 10.5 mL) was dissolved in methanol (200 mL) at 0°C. After stirring at 0°C for 10 minutes, 5-bromo-2-(methylthio)pyrimidine-4-carboxylic acid (25 g, 1 equiv) was added slowly over 15 minutes. The reaction solution was refluxed for 4 hours and cooled. After the reaction was completed, the reaction solution was concentrated under reduced pressure. The concentrate was diluted with dichloromethane, and then washed with saturated aqueous sodium bicarbonate, and then brine. The organic layer was dried over magnesium sulfate and concentrated. The concentrate was recrystallized from ethyl acetate and hexane, and then filtered to obtain the title compound (20 g, 76% yield) in yellow color.
[0434] 1 H-NMR: (400M...
Embodiment 2
[0482] N-(3-(2-((2-hydroxyethyl)amino)-7-methyl-8-oxo-7,8-dihydropyrido[3,4-d]pyrimidin-6-yl) -4-methylphenyl)-3-(trifluoromethyl)benzamide
[0483]
[0484] The experimental method is the same as that in Example 1, except that in step 12, 2-aminoethanol is used instead of cyclopropylamine. LCMS (ESI): 498 (M+H) + .
Embodiment 3
[0486] N-(4-methyl-3-(7-methyl-2-(methylamino)-8-oxo-7,8-dihydropyrido[3,4-d]pyrimidin-6-yl) Phenyl)-3-(trifluoromethyl)benzamide
[0487]
[0488] The experimental method is the same as that in Example 1, except that in step 12, methylamine is used instead of cyclopropylamine. LCMS (ESI): 468 (M+H) + .
PUM
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com